Refocusing on Companion Dxs, MPI to Debut Array-based Drug Response-Predictor Test Next Year
September 21, 2010
Refocusing on Companion Dxs, MPI to Debut Array-based Drug Response-Predictor Test Next Year
MPI's Drug Response Predictor pairs the company's algorithms and expertise with the Affymetrix GeneChip platform to help guide both clinical validation and patient treatment.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Clavis Pharma Taps Skyline Dx for Array-based Patient Selection in AML Drug Trial
September 6, 2011 / BioArray News - Despite Genotyping Growth, Affymetrix's Q3 Sales Fall 5 Percent on Service Slowdown
November 2, 2010 / BioArray News - Affymetrix Sees 'Opportunity' for Diagnostics Business in Increased FDA Oversight of LDTs
September 21, 2010 / BioArray News - Affy Files CytoScan with FDA, Plans 'Aggressive' Marketing Campaign to Grow Cyto Business
February 19, 2013 / BioArray News - DNA Link's Chip-Based Forensic Test Could Help ID Korean War Remains
February 12, 2013 / BioArray News